We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIOLABO SAS

Co-Diagnostics, Inc.

Co-Diagnostics, Inc. is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-a... read more Featured Products: More products

Download Mobile App




Compact POCT Platform Unlocks Multiplexing Potential of Real-Time PCR

By LabMedica International staff writers
Posted on 24 Feb 2023
Print article
Image: New real-time PCR platform will detect infectious diseases in POC settings (Photo courtesy of Co-Diagnostics)
Image: New real-time PCR platform will detect infectious diseases in POC settings (Photo courtesy of Co-Diagnostics)

A new real-time PCR platform aims to disrupt the molecular diagnostics status quo by bringing revolutionary lab-grade PCR testing capabilities - the gold standard in infectious disease testing -into homes and businesses. Developed by world-renowned scientists and designed to give users the power to know, the platform will use disposable cartridges and smartphone connectivity to offer gold standard PCR testing at home, the office, and at school without the need for a lab.

Co-Diagnostics, Inc. (Salt Lake City, UT, USA) has commenced clinical evaluations for its at-home and point-of-care Co-Dx PCR Home platform and initial COVID-19 test, consisting of the clinical trials and analytical studies that are expected to support submissions to the US FDA and other regulatory bodies. The company has developed the real-time PCR platform for the detection of infectious diseases in at-home and point-of-care settings. Co-Diagnostics plans to come out with multiplex panels after receiving the initial regulatory authorization for the platform.

"The commencement of our clinical evaluations represents the achievement of a profound milestone for our company. It is the culmination of a development process that spans over two years of research and development and has harnessed the expert skills of well over a hundred dedicated scientists, engineers, and support staff. The new at-home and point-of-care testing (POCT) platform represents a high degree of innovation that brings together the power of our patented Co-Primer™ technology coupled with other proprietary IP, setting a new standard for compact POCT that unlocks the multiplexing potential of real-time PCR," said Dwight Egan, CEO of Co-Diagnostics. "We believe this invention holds significant promise for the United States and around the world, including regions of the globe that have not previously had access to the quality-of-life advantages of inexpensive, powerful, accurate diagnostic technology. We are excited to begin these clinical evaluations and to leverage the power of our groundbreaking science in this new and revolutionary platform."

Related Links:
Co-Diagnostics, Inc.

Unit-Dose Twist-Tip BFS
New
Gold Supplier
HDL Subfractions Kit
Lipoprint HDL Subfractions Kit
New
Diagnostic Salivary DHEA ELISA Kit
Salimetrics Salivary DHEA Enzyme Immunoassay Kit
New
Platinum Supplier
Ultra-Low PSA Control
Prostate-Specific Antigen Control

Print article

Channels

Clinical Chem.

view channel
Image: Electrochemical cells etched by laser on wooden tongue depressor measure glucose and nitrite in saliva (Photo courtesy of Analytical Chemistry)

Biosensor-Fabricated Wooden Tongue Depressor Measures Glucose and Nitrite in Saliva

Physicians often use tongue depressors to examine a patient's mouth and throat. However, it is hard to imagine that this simple wooden tool could actively assess a patient's health. This idea has led to... Read more

Molecular Diagnostics

view channel
Image: PrecisionCHD offers 75% higher sensitivity than conventional testing methods (Photo courtesy of Cardio Diagnostics)

New Diagnostic Approach Combines DNA Testing With AI Analysis for Coronary Heart Disease Risk Assessment

Despite significant progress in medical science, heart disease continues to be a leading cause of death across the globe. Early diagnosis is key for implementing preventive actions, but current methods... Read more

Hematology

view channel
Image: The Atellica HEMA 570 and 580 hematology analyzers remove workflow barriers (Photo courtesy of Siemens)

Next-Gen Hematology Analyzers Eliminate Workflow Roadblocks and Achieve Fast Throughput

Hematology testing is a critical aspect of patient care, utilized to establish a patient's health baseline, track treatment progress, or guide timely modifications to care. However, increasing constraints... Read more

Immunology

view channel
Image: Newly observed anti-FSP antibodies have also been found to predict immune-related adverse events (Photo courtesy of Calviri)

First Blood-Based Biomarkers Test to Predict Treatment Response in Cancer Patients

Every year worldwide, lung cancer afflicts over two million individuals and almost the same number of people succumb to the disease. This malignancy leads the charts in cancer-related mortalities, with... Read more

Microbiology

view channel
Image: The T2Biothreat Panel runs on the T2Dx Instrument (Photo courtesy of T2 Biosystems)

Fully-Automated, Direct-From-Blood Test Rapidly Detects Multiple Biothreat Pathogens

During a public health emergency involving biothreat pathogens, rapid and accurate diagnostic testing is vital for reducing health and economic consequences. Infections by these pathogens, if not promptly... Read more

Pathology

view channel
Image: navify digital solutions can helping labs mitigate unique quality challenges (Photo courtesy of Roche)

Cloud-Based Digital Solution Allows Labs to Track Test Samples along Entire Diagnostic Journey

Diagnosing a disease involves a meticulous procedure of monitoring a patient's diagnostic sample throughout its entire journey, which aids in clinical decision-making. However, there aren't any standardized... Read more

Technology

view channel
Electronic biosensor uses DNA aptamers for detecting biomarkers in whole blood samples (Photo courtesy of Freepik)

Electronic Biosensor Detects Biomarkers in Whole Blood Samples without Addition of Reagents

The absence of robust, reliable, and user-friendly bioanalytical tools for early and timely diagnosis of cardiovascular diseases, particularly sudden cardiac arrest, leads to preventable deaths and imposes... Read more

Industry

view channel
Image: The global hemostasis diagnostics market is expected to reach USD 3.95 billion by 2025 (Photo courtesy of Freepik)

Global Hemostasis Diagnostics Market Driven by Increase in Invasive Surgical Procedures

Injury or surgery naturally creates bleeding in living beings, which must be stopped to prevent excessive blood loss. The human body implements a protective mechanism known as hemostasis to stop excessive bleeding.... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.